Draft Guidance on Nicotine Polacrilex

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Nicotine polacrilex

**Dosage Form: Route:** Troche/lozenge (mini); oral

**Recommended Studies:** One study

1. **Type of study:** Fasting  
   **Design:** Single-dose, two-way crossover in vivo  
   **Strength:** EQ 4 mg base  
   **Subjects:** Males and non-pregnant, non-lactating females, general smoking population  
   **Additional comments:** Place the lozenge in the mouth and allow the lozenge to slowly dissolve; minimizing swallowing. Do not chew or swallow lozenge.

**Analytes to measure (in appropriate biological fluid):** Nicotine in plasma

**Bioequivalence based on (90% CI):** Nicotine

**Waiver request of in vivo testing:** EQ 2 mg base (mint flavor) based on (i) acceptable bioequivalence study on the EQ 4 mg base strength (mint flavor), (ii) acceptable in-vitro dissolution testing on all strengths, and (iii) proportional similarity of the formulation across all strengths.

Lozenges with an alternate flavor (EQ 2 mg base and EQ 4 mg base) may be eligible for a waiver of the bioequivalence study requirements based on (1) an acceptable bioequivalence study on the 4 mg strength (mint flavor), (2) acceptable dissolution testing on all strengths and flavors, (3) proportional similarity in the formulations of all strengths and flavors, and (4) the alternate flavor (the inactives) has been approved for the same route of administration.

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).